[Form 4] Artivion, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc. (AORT), exercised stock options and sold an equal number of shares on 08/27/2025. He exercised a stock option with an $11.03 exercise price to acquire 18,200 shares and simultaneously sold 18,200 shares at a weighted average price of $44.023 per share. Following these transactions, Mr. Stanton beneficially owned 64,200 shares of Artivion common stock.

The option exercised had an original grant with a first exercisable date of 11/08/2023 and a stated vesting schedule of 33 1/3% per year. The filing notes the sale price range was $43.84 to $44.26 and that the reporting person can provide a breakdown of shares sold at each price upon request.

Positive

• Option exercise executed: 18,200 shares acquired by exercising options at $11.03, indicating use of vested compensation instruments
• Transparent pricing disclosure: Weighted average sale price provided ($44.023) and range ($43.84–$44.26), with offer to supply per-price breakdown on request

Negative

• Insider sale reduced direct ownership: Beneficial ownership decreased to 64,200 shares after the transactions
• Equal-sized sale following exercise: All 18,200 acquired shares were sold the same day, representing insider liquidity rather than long-term hold

Insights

Corporate Governance Expert

TL;DR: Insider exercised options and sold shares on the same day, reducing direct holdings to 64,200 shares.

These Form 4 entries document a routine option exercise followed by a sale equal to the number of shares acquired, leaving the reporting person with 64,200 shares beneficially owned. The filing discloses the exercise price of $11.03 and a weighted average sale price of $44.023, plus the sale price range. This is a straightforward Section 16 disclosure; it does not itself indicate corporate governance changes or new compensation terms beyond the previously granted option vesting schedule.

Securities Analyst

TL;DR: Insider realized value by exercising low-strike options and selling at ~$44; remaining ownership is disclosed precisely.

The report shows a stock option with an $11.03 strike was exercised for 18,200 shares and those shares were sold the same day at a weighted average of $44.023, with prices ranging $43.84–$44.26. Post-transaction direct ownership is 64,200 shares and no derivative holdings remain for the reported option. This Form 4 provides clear transactional details useful for tracking insider liquidity and ownership levels.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stanton Marshall S.

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical & MD Affair

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		M		18,200	A	$11.03	82,400	D
Common Stock	08/27/2025		S		18,200	D	$44.023(1)	64,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.03	08/27/2025		M			18,200	11/08/2023(2)	11/08/2029	Common Stock	18,200	$0	0	D

Explanation of Responses:

1. Reflects weighted average price. Range of prices were between $43.84 to $44.26. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.

Remarks:

	/s/ Marshall Stanton	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Marshall S. Stanton report on Form 4 for AORT?

He exercised 18,200 stock options at $11.03 and sold 18,200 shares on 08/27/2025 at a weighted average price of $44.023.

How many Artivion (AORT) shares does the reporting person own after the transactions?

The reporting person beneficially owned 64,200 shares of common stock following the reported transactions.

What were the exercise and sale prices reported on the Form 4?

Exercise price: $11.03 per share; weighted average sale price: $44.023 per share; sale price range: $43.84–$44.26.

When was the option first exercisable and what is the vesting schedule?

The first exercisable date was 11/08/2023 and the option vests 33 1/3% per year beginning on the first anniversary of the grant date.

Does the Form 4 indicate any remaining derivative securities for the reporting person?

No derivative securities from the reported option are shown as beneficially owned following the transactions (0 derivative securities reported).